Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: a meta-analysis.
about
Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trialsRisk of venous thromboembolic events associated with VEGFR-TKIs: a systematic review and meta-analysisIncidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patientsRisk of Hyponatraemia in Cancer Patients Treated with Targeted Therapies: A Systematic Review and Meta-Analysis of Clinical TrialsTreatment-related severe and fatal adverse events with molecular targeted agents in the treatment of advanced gastric cancer: a meta-analysis.Risk of treatment-related deaths with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis of 41 randomized controlled trials.Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials.Incidence and risk of treatment-related mortality with mTOR inhibitors everolimus and temsirolimus in cancer patients: a meta-analysisRisk of treatment-related mortality with sorafenib in cancer patients: a meta-analysis of 20 randomly controlled trials : Risk of sorafenib-associated death.Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysisTreatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials.Update on Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on QT Interval, Left Ventricular Dysfunction and Overall Risk/Benefit.Activation of an AKT/FOXM1/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer.Risk of serious adverse events and fatal adverse events with sorafenib in patients with solid cancer: a meta-analysis of phase 3 randomized controlled trials†.Sudden cardiac death in a patient with advanced hepatocellular carcinoma with good response to sorafenib treatment: A case report with literature analysis.Adverse events risk associated with anti-VEGFR agents in the treatment of advanced nonsmall-cell lung cancer: A meta-analysis.Risks associated with sunitinib use and monitoring to improve patient outcomes.Targeted Therapy for Medullary Thyroid Cancer: A Review.Meta-analysis of randomized controlled trials for the incidence and risk of fatal adverse events in cancer patients treated with ipilimumab.Treatment-related mortality with aflibercept in cancer patients: a meta-analysis.Fatal adverse events with molecular targeted agents in the treatment of advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials
P2860
Q26822790-52B9839F-1162-4D96-9140-5509E74A0A7FQ27026453-2D953141-E70B-48E6-B195-562D0FADC783Q28079328-C7B4B348-4D94-4F7E-BB03-A1AC5D721085Q28551983-43F0A2BD-3DC9-4B6F-85F6-E34F9FA37C30Q33631305-FBAE58B9-F25C-4BA9-9171-FE7245BFCD8CQ34352627-B6D3A755-24EA-44A0-A101-37A1F22089A0Q34554398-934305B1-F2C6-47C8-9012-5D8CCB4D309DQ34778631-5B4F3B49-463C-4BD2-80E7-5BE879CBA325Q35691234-73D7D409-9F2F-44ED-9B54-7812BA3B130EQ36594084-8C92CD4B-6BB3-43E3-BA4C-B0301CB0D3FDQ38177768-0CEDEC37-B390-4926-8A0A-A235B108C9EDQ38501976-392B3B53-3A45-460F-9706-C1406BA22CBFQ38603815-897D380E-E864-4B0F-BAAF-79F3C3F0FA1AQ39258192-B8A80005-E275-46B5-9419-BC994AEE736DQ42136590-391BB8C4-B4E5-4532-B754-E74609805B54Q42359608-05E4FF5D-977A-4FA7-93B0-EFB8BBB5D5F8Q42433181-41D7B7A3-924F-4E00-9300-B2DC7E88B2F2Q49328959-772B4CC7-2CBD-42BA-BBDE-558036EB7C3DQ51104725-2EEBDC05-D6C9-4340-8D68-17F70420F2FDQ54386535-8CE26A78-6619-49A9-B7E7-BCFF4C25E2A2Q57073605-144C9FD7-75E3-40D5-99FC-AE8F084589C0
P2860
Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: a meta-analysis.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Treatment-related mortality wi ...... solid tumors: a meta-analysis.
@en
type
label
Treatment-related mortality wi ...... solid tumors: a meta-analysis.
@en
prefLabel
Treatment-related mortality wi ...... solid tumors: a meta-analysis.
@en
P2093
P1476
Treatment-related mortality wi ...... solid tumors: a meta-analysis.
@en
P2093
Guru Sonpavde
Louis J Portas
Matthew D Galsky
Menggang Yu
Shanthi Sivendran
P304
P356
10.1016/J.CTRV.2012.05.001
P577
2012-05-30T00:00:00Z